RCKT

Rocket Pharmaceuticals, Inc.

A developer of gene therapies for rare, life-threatening genetic diseases, Rocket Pharmaceuticals works to correct the underlying genetic defects behind conditions like Danon disease and leukocyte adhesion deficiency. Founded in 2015 and merged with Inotek Pharmaceuticals in 2018, the company's name reflects its "moonshot" ambition to bring speed to medicine. Its therapies either modify a patient's own blood stem cells outside the body or deliver corrected genes directly via engineered viruses.